658 related articles for article (PubMed ID: 24154707)
21. [Renin inhibition and the kidney].
Ecder T
Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():28-31. PubMed ID: 20019474
[TBL] [Abstract][Full Text] [Related]
22. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.
Fisher ND; Jan Danser AH; Nussberger J; Dole WP; Hollenberg NK
Circulation; 2008 Jun; 117(25):3199-205. PubMed ID: 18559696
[TBL] [Abstract][Full Text] [Related]
23. Aliskiren as a novel therapeutic agent for hypertension and cardio-renal diseases.
Rashikh A; Ahmad SJ; Pillai KK; Najmi AK
J Pharm Pharmacol; 2012 Apr; 64(4):470-81. PubMed ID: 22420653
[TBL] [Abstract][Full Text] [Related]
24. Blood Pressure Lowering and Safety Improvements With Liver Angiotensinogen Inhibition in Models of Hypertension and Kidney Injury.
Mullick AE; Yeh ST; Graham MJ; Engelhardt JA; Prakash TP; Crooke RM
Hypertension; 2017 Sep; 70(3):566-576. PubMed ID: 28716988
[TBL] [Abstract][Full Text] [Related]
25. A comparison of the antihypertensive and anti-inflammatory effects of aliskiren and ramipril add-on therapy in peritoneal dialysis patients--a pilot open label study.
Makówka A; Olejniczak-Fortak M; Nowicki M
Kidney Blood Press Res; 2012; 36(1):18-25. PubMed ID: 22777192
[TBL] [Abstract][Full Text] [Related]
26. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
[TBL] [Abstract][Full Text] [Related]
27. Direct renin inhibition in a rat model of chronic allograft injury.
Rusai K; Schmaderer C; Hermans JJ; Lutz J; Heemann U; Baumann M
Transplantation; 2011 Nov; 92(9):999-1004. PubMed ID: 21956196
[TBL] [Abstract][Full Text] [Related]
28. Direct renin inhibition: focus on aliskiren.
Pool JL
J Manag Care Pharm; 2007 Oct; 13(8 Suppl B):21-33. PubMed ID: 17970614
[TBL] [Abstract][Full Text] [Related]
29. Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors?
Wiggins KJ; Kelly DJ
Kidney Int; 2009 Jul; 76(1):23-31. PubMed ID: 19367328
[TBL] [Abstract][Full Text] [Related]
30. A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes.
Major TC; Olszewski B; Rosebury W; Okerberg C; Carlson T; Ostroski R; Schroeder R; Kowala MC; Leadley R
Cardiovasc Drugs Ther; 2008 Dec; 22(6):469-78. PubMed ID: 18679781
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions.
Angeli F; Reboldi G; Mazzotta G; Poltronieri C; Garofoli M; Ramundo E; Biadetti A; Verdecchia P
Curr Drug Saf; 2012 Feb; 7(1):76-85. PubMed ID: 22663961
[TBL] [Abstract][Full Text] [Related]
32. Long-term antihypertensive effects of aliskiren, a direct renin inhibitor, in chronic hemodialysis patients.
Ishimitsu T; Ohta S; Ohno E; Takahashi T; Numabe A; Okamura A; Ohba S; Hashimoto A; Matsuoka H
Ther Apher Dial; 2013 Oct; 17(5):524-31. PubMed ID: 24107281
[TBL] [Abstract][Full Text] [Related]
33. Clinical pharmacokinetics and pharmacodynamics of aliskiren.
Vaidyanathan S; Jarugula V; Dieterich HA; Howard D; Dole WP
Clin Pharmacokinet; 2008; 47(8):515-31. PubMed ID: 18611061
[TBL] [Abstract][Full Text] [Related]
34. Greater reductions in plasma aldosterone with aliskiren in hypertensive patients with higher soluble (Pro)renin receptor level.
Bokuda K; Morimoto S; Seki Y; Yatabe M; Watanabe D; Yatabe J; Ando T; Shimizu S; Itoh H; Ichihara A
Hypertens Res; 2018 Jun; 41(6):435-443. PubMed ID: 29618841
[TBL] [Abstract][Full Text] [Related]
35. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
Dalla Vestra M; Simioni N; Masiero A
Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
[TBL] [Abstract][Full Text] [Related]
36. Aliskiren, the future of renin-angiotensin system blockade?
Uresin Y; Mehtar Bozkurt M; Sabirli S; Ozunal ZG
Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):835-49. PubMed ID: 17867914
[TBL] [Abstract][Full Text] [Related]
37. Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model.
Leelahavanichkul A; Yan Q; Hu X; Eisner C; Huang Y; Chen R; Mizel D; Zhou H; Wright EC; Kopp JB; Schnermann J; Yuen PS; Star RA
Kidney Int; 2010 Dec; 78(11):1136-53. PubMed ID: 20736988
[TBL] [Abstract][Full Text] [Related]
38. New insights into the renoprotective actions of the renin inhibitor aliskiren in experimental renal disease.
Feldman DL
Hypertens Res; 2010 Apr; 33(4):279-87. PubMed ID: 20203685
[TBL] [Abstract][Full Text] [Related]
39. Renoprotection by Direct Renin Inhibition: A Systematic Review and Meta- Analysis.
Louvis N; Coulson J
Curr Vasc Pharmacol; 2018 Jan; 16(2):157-167. PubMed ID: 28464775
[TBL] [Abstract][Full Text] [Related]
40. [Renal tissue angiotensins during converting enzyme inhibition of angiotensin I in spontaneously hypertensive rat].
Ingert C; Grima M; Michel B; Barthelmebs M; Imbs JL
Arch Mal Coeur Vaiss; 1997 Aug; 90(8):1135-41. PubMed ID: 9404423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
